Efficacy and safety of apixaban compared with aspirin in patients who previously tried but failed treatment with vitamin K antagonists: Results from the AVERROES trial

European Heart Journal

Volumn 35, Issue 28, 2014, Pages 1856-1863

  Coppens, Michiel ^a,b   Synhorst, David ^c   Eikelboom, John W ^a   Yusuf, Salim ^a   Shestakovska, Olga ^a   Connolly, Stuart J ^a  

^a MCMASTER UNIVERSITY   (Canada)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

^c BRISTOL MYERS SQUIBB   (United States)

Author keywords

Apixaban; Aspirin; Atrial fibrillation; Bleeding; Stroke; Vitamin K antagonists

Indexed keywords

ACETYLSALICYLIC ACID; ANTIVITAMIN K; APIXABAN; BLOOD CLOTTING FACTOR 10A INHIBITOR; FIBRINOLYTIC AGENT; PYRAZOLE DERIVATIVE; PYRIDONE DERIVATIVE; VITAMIN K GROUP;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; BLEEDING; BODY MASS; CEREBROVASCULAR ACCIDENT; CHADS2 SCORE; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; DRUG TREATMENT FAILURE; EMBOLISM; HEART ATRIUM FIBRILLATION; HEART FAILURE; HUMAN; INTERNATIONAL NORMALIZED RATIO; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MIDDLE AGED; MODERATE RENAL IMPAIRMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK REDUCTION; SEX RATIO; ANTAGONISTS AND INHIBITORS; CHEMICALLY INDUCED; CLINICAL TRIAL; COMPARATIVE STUDY; COMPLICATION; DRUG ADMINISTRATION; FEMALE; MALE; MULTICENTER STUDY; RISK FACTOR; STROKE; TREATMENT OUTCOME;

AGED; ASPIRIN; ATRIAL FIBRILLATION; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FACTOR XA INHIBITORS; FEMALE; FIBRINOLYTIC AGENTS; HEMORRHAGE; HUMANS; MALE; PYRAZOLES; PYRIDONES; RISK FACTORS; STROKE; TREATMENT OUTCOME; VITAMIN K;

EID: 84904981829     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/ehu048     Document Type: Article

References (13)

1. Hart RG, Pearce LA, Aguilar MI. Meta-Analysis: Antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 2007; 146:857-867
2. You JJ, Singer DE, Howard PA, Lane DA, Eckman MH, Fang MC, Hylek EM, Schulman S, Go AS, Hughes M, Spencer FA, Manning WJ, Halperin JL, LipGY. Antithrombotic therapy for atrial fibrillation: Antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012;141(2 Suppl):e531S-e575S.
3. Go AS, Hylek EM, Borowsky LH, Phillips KA, Selby JV, Singer DE. Warfarin use among ambulatory patients with nonvalvular atrial fibrillation: The anticoagulation and risk factors in atrial fibrillation (ATRIA) study. Ann Intern Med 1999;131:927-934
4. Nieuwlaat R, Capucci A, Lip GY, Olsson SB, Prins MH, Nieman FH, Lopez-Sendon J, Vardas PE, Aliot E, Santini M, Crijns HJ. Antithrombotic treatment in real-life atrial fibrillation patients: A report from the Euro Heart Survey on Atrial Fibrillation. Eur Heart J 2006;27:3018-3026
5. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom JW, Oldgren J, Parekh A, Pogue J, Reilly PA, Themeles E, Varrone J, Wang S, Alings M, Xavier D, Zhu J, Diaz R, Lewis BS, Darius H, Diener HC, Joyner CD, Wallentin L. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009;361:1139-1151
6. Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, Al-Khalidi HR, Ansell J, Atar D, Avezum A, Bahit MC, Diaz R, Easton JD, Ezekowitz JA, Flaker G, Garcia D, Geraldes M, Gersh BJ, Golitsyn S, Goto S, Hermosillo AG, Hohnloser SH, Horowitz J, Mohan P, Jansky P, Lewis BS, Lopez-Sendon JL, Pais P, Parkhomenko A, Verheugt FW, Zhu J, Wallentin L. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011;365: 981-992
7. Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, Breithardt G, Halperin JL, Hankey GJ, Piccini JP, Becker RC, Nessel CC, Paolini JF, Berkowitz SD, Fox KA, Califf RM. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011;365:883-891
8. Connolly SJ, Eikelboom JW, Joyner C, Diener HC, Hart R, Golitsyn S, Flaker G, Avezum A, Hohnloser SH, Diaz R, Talajic M, Zhu J, Pais P, Budaj A, Parkhomenko A, Jansky P, Commerford P, Tan RS, Sim KH, Lewis BS, Van MW, Lip GY, Kim JH, Lanas-Zanetti F, Gonzalez-Hermosillo A, Dans AL, Munawar M, O-Donnell M, Lawrence J, Lewis G, Afzal R, Yusuf S. Apixaban in patients with atrial fibrillation. N Engl J Med 2011;364:806-817
9. Eikelboom JW, O-Donnell M, Yusuf S, Diaz R, Flaker G, Hart R, Hohnloser S, Joyner C, Lawrence J, Pais P, Pogue J, Synhorst D, Connolly SJ. Rationale and design of AVERROES: Apixaban versus acetylsalicylic acid to prevent stroke in atrial fibrillation patients who have failed or are unsuitable for vitamin K antagonist treatment. Am Heart J 2010;159:348-353
10. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF III, Feldman HI, Kusek JW, Eggers P, Van LF, Greene T, Coresh J. A new equation to estimate glomerular filtration rate. Ann Intern Med 2009;150:604-612
11. Camm AJ, Lip GY, De Caterina R, Savelieva I, Atar D, Hohnloser SH, Hindricks G, Kirchhof P, Bax JJ, Baumgartner H, Ceconi C, Dean V, Deaton C, Fagard R, Funck-Brentano C, Hasdai D, Hoes A, Kirchhof P, Knuuti J, Kolh P, McDonagh T, Moulin C, Popescu BA, Reiner Z, Sechtem U, Sirnes PA, Tendera M, Torbicki A, Vahanian A, Windecker S, Vardas P, Al-Attar N, Alfieri O, Angelini A, Blomstrom-Lundqvist C, Colonna P, De SJ, Ernst S, Goette A, Gorenek B, Hatala R, Heidbuchel H, Heldal M, Kristensen SD, Kolh P, Le Heuzey JY, Mavrakis H, Mont L, Filardi PP, Ponikowski P, Prendergast B, Rutten FH, Schotten U, Van Gelder IC, Verheugt FW. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: An update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J 2012;33:2719-2747
12. Connolly SJ, Pogue J, Hart RG, Hohnloser SH, Pfeffer M, Chrolavicius S, Yusuf S. Effect of clopidogrel added to aspirin in patients with atrial fibrillation. N Engl J Med 2009;360:2066-2078
13. Ezekowitz MD, Wallentin L, Connolly SJ, Parekh A, Chernick MR, Pogue J, Aikens TH, Yang S, Reilly PA, Lip GY, Yusuf S. Dabigatran and warfarin in vitamin K antagonistnaive and-experienced cohorts with atrial fibrillation. Circulation 2010;122: 2246-2253.